| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Authors’ Reply to Robert P. Giugliano and Colleagues’ Comment on: “Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance”
|
Raschi, Emanuel
|
|
|
44 |
4 |
p. 505-506
|
artikel
|
| 2 |
Comment on: “Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance”
|
Giugliano, Robert P.
|
|
|
44 |
4 |
p. 503-504
|
artikel
|
| 3 |
Communicating About Risks and Safe Use of Medicines
|
Edwards, I. Ralph
|
|
|
44 |
4 |
p. 499-501
|
artikel
|
| 4 |
Comparative Risk Assessment of Severe Uterine Bleeding Following Exposure to Direct Oral Anticoagulants: A Network Study Across Four Observational Databases in the USA
|
Weaver, James
|
|
|
44 |
4 |
p. 479-497
|
artikel
|
| 5 |
Correction to: Assessing the Safety of COVID-19 Vaccines: A Primer
|
Petousis-Harris, Helen
|
|
|
44 |
4 |
p. 507
|
artikel
|
| 6 |
Correction to: 19th ISoP Annual Meeting “New Opportunities for New Generations” Bogotá, Colombia, 26–29 October, 2019
|
|
|
|
44 |
4 |
p. 509
|
artikel
|
| 7 |
Evaluation of the Risk of Inflammatory Bowel Disease after the HPV Vaccination in Primary Care in Spain: A Time-Varying Cohort Analysis of Around 390,000 Girls
|
Martín-Merino, Elisa
|
|
|
44 |
4 |
p. 455-466
|
artikel
|
| 8 |
French Pharmacovigilance Public System and COVID-19 Pandemic
|
Grandvuillemin, Aurélie
|
|
|
44 |
4 |
p. 405-408
|
artikel
|
| 9 |
ISoP Fellowships: Recognising and Promoting Leaders in Pharmacovigilance
|
McCarthy, Deirdre
|
|
|
44 |
4 |
p. 403-404
|
artikel
|
| 10 |
Provision and Need for Medicine Information in Asia and Africa: A Scoping Review of the Literature
|
Nualdaisri, Pitchaya
|
|
|
44 |
4 |
p. 421-437
|
artikel
|
| 11 |
Real-World Fetal Exposure to Acne Treatments in the United States: A Retrospective Analysis from 2006 to 2015
|
Albogami, Yasser
|
|
|
44 |
4 |
p. 447-454
|
artikel
|
| 12 |
Risk Management for the 21st Century: Current Status and Future Needs
|
Mouchantaf, Rania
|
|
|
44 |
4 |
p. 409-419
|
artikel
|
| 13 |
Safety Consequences of Off-Label Drugs Used for COVID-19
|
Dasgupta, Nabarun
|
|
|
44 |
4 |
p. 399-402
|
artikel
|
| 14 |
Safety of As-Needed Budesonide-Formoterol in Mild Asthma: Data from the Two Phase III SYGMA Studies
|
FitzGerald, J. Mark
|
|
|
44 |
4 |
p. 467-478
|
artikel
|
| 15 |
The DIANA Study: Continued Access to Darunavir/Ritonavir (DRV/r) and Long-Term Safety Follow-Up in HIV-1-Infected Pediatric Patients Aged 3 to < 18 Years
|
Violari, Avy
|
|
|
44 |
4 |
p. 439-446
|
artikel
|
Tijdschrift beschrijving